B15. IMMUNOTHERAPY FOR LUNG DISEASE

Benralizumab for Chronic Obstructive Pulmonary Disease: Results of the Phase III GALATHEA Trial

Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2626 G. Criner, B. Celli, C. Brightling, A. Agustí, A. Papi, F. Sciurba, D. Sin, C. Vogelmeier, M. Kato, V. Shih, M. Jison, P. Newbold, M. Goldman, U. Martin

Dupilumab Reduces Severe Exacerbations and Improves Lung Function Regardless of Baseline Bronchodilator Reversibility in Patients with Uncontrolled Moderate-to-Severe Asthma Enrolled in the LIBERTY ASTHMA QUEST Study

Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2624 I. Pavord, M. Castro, K. Rabe, N. Hanania, A. Papi, J. Fitzgerald, M. Rice, P. Rowe, Y. Lu, N. Amin, H. Staudinger, N. Graham, A. Teper

A Dose-Ranging Study (TERRANOVA) of Benralizumab for Moderate to Severe Chronic Obstructive Pulmonary Disease

Pub Date : 2019-05-01 DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2625 B. Celli, G. Criner, D. Singh, M. Bafadhel, V. Backer, A. Ramírez-Venegas, Y.-F. Wei, L. Bjermer, V. Shih, S. O'Quinn, Natalya Makulova, P. Newbold, M. Goldman, U. Martin